Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Publication in refereed journal


引用次數
替代計量分析
.

其它資訊
摘要Despite recent advances in the understanding of the biologic basis of hepatocellular carcinoma (HCC) development, the clinical management of the disease remains a major challenge. Deregulation of the PI3K/Akt/mTOR pathway, which is a prototypic survival pathway, is increasingly implicated in HCC carcinogenesis. In this article, we detailed the role of this pathway in the pathogenesis of HCC and provide an update on the preclinical and clinical development of various agents targeting this key survival/proliferation pathway, which include various PI3K inhibitors, Akt inhibitors and mTOR inhibitors for HCC. In addition, we highlighted the therapeutic potential of combination strategy for mTOR inhibitors with conventional chemotherapy, in particular, antimicrotubule agents, other molecular targeting agents, as well as radiotherapy.
著者Zhou Q, Lui VWY, Yeo W
期刊名稱Future Oncology
出版年份2011
月份10
日期1
卷號7
期次10
出版社Future Medicine
頁次1149 - 1167
國際標準期刊號1479-6694
電子國際標準期刊號1744-8301
語言英式英語
關鍵詞combined targeting; hepatocellular carcinoma; PI3K/Akt/mTOR
Web of Science 學科類別Oncology; ONCOLOGY

上次更新時間 2020-03-12 於 23:35